DIAGNOSISIN VITROOF MULTIPLE SCLEROSIS

Multiple sclerosis (MS) is a demyelinating neurodegenerative disease that affects approximately 2.3 million people worldwide. To date, there is no single test available that can definitely and indisputably confirm the diagnosis of MS, just as there are no diagnostic or predictive bio-markers for the...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	GRANDI, Nicole, TRAMONTANO, Enzo, PISANO, Maria Paola
Format:	Patent
Sprache:	eng ; fre
Schlagworte:	BEER BIOCHEMISTRY CHEMISTRY COMPOSITIONS OR TEST PAPERS THEREFOR CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL ORENZYMOLOGICAL PROCESSES ENZYMOLOGY MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEICACIDS OR MICROORGANISMS METALLURGY MICROBIOLOGY MUTATION OR GENETIC ENGINEERING PROCESSES OF PREPARING SUCH COMPOSITIONS SPIRITS VINEGAR WINE
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Multiple sclerosis (MS) is a demyelinating neurodegenerative disease that affects approximately 2.3 million people worldwide. To date, there is no single test available that can definitely and indisputably confirm the diagnosis of MS, just as there are no diagnostic or predictive bio-markers for the disease. The present invention relates to a new method for the in vitro diagnosis of multiple sclerosis. In particular, the invention has as its object the analysis of the expression levels of specific transcripts deriving from Human Endogenous Retroviruses (HERV). La sclérose en plaques (SEP) est une maladie neurodégénérative démyélinisante qui affecte environ 2,3 millions de personnes dans le monde. A ce jour, il n'y a pas d'essai unique disponible qui peut confirmer de manière sûre et indiscutable le diagnostic de SEP, simplement étant donné qu'il n'y a pas de marqueurs biologiques diagnostiques ou prédictifs pour la maladie. La présente invention concerne un nouveau procédé de diagnostic in vitro de la sclérose en plaques. En particulier, l'invention a pour objet l'analyse des niveaux d'expression de transcrits spécifiques issus de rétrovirus endogènes humains (HERV).